Safety and Biomarker Response to (+)-Epicatechin in Becker Muscular Dystrophy
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, dose escalation study aimed at evaluating the safety, early
efficacy and potential biomarkers of (+)-epicatechin in patients with Becker or Becker-like
Muscular Dystrophy (BMD).